Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025GlobeNewsWire • 02/11/25
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/10/25
How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18%Zacks Investment Research • 11/25/24
AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains?Zacks Investment Research • 10/14/24
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®GlobeNewsWire • 09/06/24
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High?Zacks Investment Research • 08/23/24